Syngene International Intrinsic Value
SYNGENE • Healthcare
Current Stock Price
₹390.90
Primary Intrinsic Value
₹146.96
Market Cap
₹157.5K Cr
-53.0%
Downside
Median Value
₹183.82
Value Range
₹117 - ₹374
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
SYNGENE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹146.96 | ₹117.57 - ₹176.35 | -62.4% | EPS: ₹6.68, Sector P/E: 22x |
| Book Value Method | asset | ₹234.59 | ₹211.13 - ₹258.05 | -40.0% | Book Value/Share: ₹117.30, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹183.82 | ₹165.44 - ₹202.20 | -53.0% | Revenue/Share: ₹91.91, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹213.40 | ₹192.06 - ₹234.74 | -45.4% | EBITDA: ₹860.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹373.89 | ₹299.11 - ₹448.67 | -4.4% | CF Growth: 13.6%, Discount: 15% |
| PEG Ratio Method | growth | ₹117.27 | ₹105.54 - ₹129.00 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹117.27 | ₹105.54 - ₹129.00 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹195.45 | ₹175.91 - ₹215.00 | -50.0% | ROE: 5.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹132.78 | ₹119.50 - ₹146.06 | -66.0% | EPS: ₹6.68, BVPS: ₹117.30 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SYNGENE Intrinsic Value Analysis
What is the intrinsic value of SYNGENE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Syngene International (SYNGENE) is ₹183.82 (median value). With the current market price of ₹390.90, this represents a -53.0% variance from our estimated fair value.
The valuation range spans from ₹117.27 to ₹373.89, indicating ₹117.27 - ₹373.89.
Is SYNGENE undervalued or overvalued?
Based on our multi-method analysis, Syngene International (SYNGENE) appears to be trading above calculated value by approximately 53.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.40 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Syngene International
Additional stock information and data for SYNGENE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,168 Cr | ₹796 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,042 Cr | ₹795 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹824 Cr | ₹498 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹581 Cr | ₹276 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹701 Cr | ₹387 Cr | Positive Free Cash Flow | 8/10 |